Status:
COMPLETED
An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes patients across ten countries across the world. Participants will be asked to give information ab...
Eligibility Criteria
Inclusion
- Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
- Male or female, age more than or equal to 18 years at the time of signing informed consent (in Algeria more than or equal to 19 years; in Japan more than or equal to 20 years).
- Diagnosed with T2DM more than or equal to 180 days prior to the day of signing the informed consent
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Diagnosed with Type 1 diabetes
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Patients with known congenital heart disease/malformation
Key Trial Info
Start Date :
December 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
7548 Patients enrolled
Trial Details
Trial ID
NCT03811288
Start Date
December 10 2018
End Date
September 30 2019
Last Update
June 9 2020
Active Locations (164)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Algiers, Algeria, 16000
2
Novo Nordisk Investigational Site
Batna City, Algeria, 05000
3
Novo Nordisk Investigational Site
Constantine, Algeria, 25000
4
Novo Nordisk Investigational Site
Tiaret, Algeria, 14000